SUNNYVALE, Calif., Aug. 21, 2015 /PRNewswire/ -- Accuray Incorporated (NASDAQ: ARAY) announced today it has received a multi-system order from 21st Century Oncology for one CyberKnife® M6™ and four TomoHDA™ Systems. These are the latest generation CyberKnife and TomoTherapy Systems, and are used worldwide to provide extremely precise radiation treatments for cancerous and non-cancerous tumors throughout the body. The TomoTherapy Systems will replace conventional linear accelerators in single vault freestanding centers, reinforcing the TomoTherapy's value as a mainstream radiation therapy device. Accuray booked the order in its first fiscal quarter of 2016.
"This latest transaction by 21st Century is the most recent example of a multiple unit order for Accuray systems," said Joshua H. Levine, president and chief executive officer of Accuray. "Whether clinicians choose to order both the CyberKnife and TomoTherapy Systems or multiple units of a single system, we believe these orders speak to the high degree of flexibility and precision our systems provide and growing market interest in our customer-driven solutions."
21st Century is the largest integrated network of cancer treatment centers and affiliated physicians in the world. The 21st Century network offers a high level of coordinated care from cancer diagnosis through surgery, radiation, and systemic treatment as required. As of June 30, 2015, the Company operated 183 treatment centers, including 148 centers located in 17 U.S. states and 35 centers located in six countries in Latin America. 21st Century strives to provide each cancer patient with state-of-the-art treatments that precisely address his or her individual needs. With the new order for the CyberKnife and TomoHDA Systems, 21st Century is supporting this goal, and positively impacting the way cancer treatments are managed at their centers.
About the CyberKnife and TomoTherapy Systems
The Accuray CyberKnife M6 Series and TomoTherapy H Series treatment solutions cover the entire spectrum of radiation therapy needs. The CyberKnife M6 Series enables precise, high-quality, high-dose distributions to be confidently delivered to the patient with extreme accuracy over a minimum number of treatments, reducing side effects and preserving patients' quality of life. The CyberKnife System is the only robotic full-body radiosurgery system available today. The TomoTherapy H Series efficiently enables physicians to customize treatment plans for the entire range of radiation therapy patients and disease types. Its innovative design enables treatment plans to be delivered with integrated, daily CT image guidance, enhancing accuracy and delivering highly precise, intensity-modulated radiation for optimal sparing of healthy tissue and critical structures.
Further information on Accuray, the CyberKnife and TomoTherapy Systems is available at www.accuray.com.
About Accuray
Accuray Incorporated (NASDAQ: ARAY) is a radiation oncology company that develops, manufactures and sells precise, innovative tumor treatment solutions that set the standard of care with the aim of helping patients live longer, better lives. The company's leading-edge technologies deliver the full range of radiation therapy and radiosurgery treatments.
Safe Harbor Statement
Statements made in this press release that are not statements of historical fact are forward-looking statements and are subject to the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995. Forward-looking statements in this press release relate, but are not limited, to market success, adoption of our products, clinical benefits of our technologies, patient outcomes and Accuray's leadership position in radiation oncology innovation and technologies. Forward-looking statements are subject to risks and uncertainties that could cause actual results to differ materially from expectations, including but not limited to the risks detailed under the heading "Risk Factors" in the company's report on Form 10-K, filed on August 29, 2014, the company's reports on Form 10-Q, filed on November 7, 2014, February 6, 2015 and May 7, 2015, and the company's other filings with the SEC.
Forward-looking statements speak only as of the date the statements are made and are based on information available to Accuray at the time those statements are made and/or management's good faith belief as of that time with respect to future events. The company assumes no obligation to update forward-looking statements to reflect actual performance or results, changes in assumptions or changes in other factors affecting forward-looking information, except to the extent required by applicable securities laws. Accordingly, investors should not put undue reliance on any forward-looking statements.
To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/accuray-awarded-multi-system-order-by-21st-century-oncology-300131678.html
SOURCE Accuray Incorporated
Investors: Chris Dailey, Investor Relations, EVC Group, +1 (646) 445-4801, Cdailey@evcgroup.com ; Media: Beth Kaplan, Public Relations Director, Accuray, +1 (408) 789-4426, bkaplan@accuray.com
